- RVX-208 Brings 77% Relative Risk Reduction Of Major Adverse Cardiovascular Events For Diabetes Mellitus Patients
In an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix, disclosed that patients with cardiovascular disease (CVD) arising from atheroscleros ...
Article - News Staff - Sep 10 2014 - 7:00am
- Keytruda: FDA Approves Melanoma Drug That Uses Immune System To Fight Cancer
The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab), a new immunotherapy drug to treat advanced melanoma after it was tested on more than 600 patients who had melanoma that had spread throughout their bodies. Because so many of the ...
Article - News Staff - Sep 12 2014 - 3:19pm
- Merck Discontinues Tecemotide For Stage III Non-Small Cell Lung Cancer
Merck is discontinuing the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). Tecemotide is an investigational MUC1 antigen-s ...
Article - News Staff - Sep 12 2014 - 7:05pm
- UM171: New Molecule Allows For 10X Increase In Adult Stem Cell Transplants
Investigators have announced discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord blood contains adult stem cells used for transplants aimed at curing a number of blo ...
Article - News Staff - Sep 18 2014 - 3:08pm
- Uterus Transplant Leads To First Successful Baby Delivery
Seven Swedish women have had embryos reintroduced after receiving wombs from living donors and now one has delivered a healthy and normally developed boy, reveals the case study in The Lancet. The uterus transplantation research project at the University ...
Article - News Staff - Oct 7 2014 - 9:29am
- The Obesity Paradox—Seriously?
Obesity is a significant risk factor for the development of a number of diseases, but the first that comes to mind is type 2 diabetes. ...
Article - Joe Cornicelli - Oct 10 2014 - 1:04pm
- E. Coli: Bacterial Diarrhea Vaccine Candidate Highly Efficacious
Each year, nearly 600,000 children die from severe, dehydrating diarrhea and millions more are hospitalized. Enterotoxigenic Escherichia coli (ETEC) may be the first enteric illness encountered by many infants, and it causes several hundred million cases ...
Article - News Staff - Oct 27 2014 - 10:31am
- The Risks And Rewards Of Two Popular Gastric Bypass Procedures
A recent study compared two of the most commonly performed bariatric surgery procedures. There are tradeoffs between the two surgical approaches in potential risks and benefits and so there has been an ongoing debate about which can achieve weight loss, w ...
Article - News Staff - Oct 30 2014 - 9:30am
- Beta-Blockers For Some Heart Failure Linked With Improved Survival
Up to 50 percent of patients with heart failure have normal or near-normal ejection fraction, termed heart failure with preserved ejection fraction (HFPEF). The risk of death in HFPEF may be as high as in heart failure with reduced ejection fraction (HFRE ...
Article - News Staff - Nov 16 2014 - 3:27pm
- Clinical Trials For Rich Patients Could Help Find Cures For Us All
Overcoming gaps in medical funding. nakrnsm, CC BY By Stephanie Swift, University of Ottawa Disease can affect any person, rich or poor. While your bank balance can’t really protect you from getting sick, it could potentially buy you – and many other pati ...
Article - The Conversation - Dec 29 2014 - 8:30am